Biomarker, Cervical Cancer, CtDNA, Immunotherapy
Conditions
Brief summary
Immunotherapy is the main option for advanced, recurrent and metastatic cervical cancer. However, due to the complex interaction between the immune system and tumors, there is still a lack of effective markers for immunotherapy. Scientists are actively searching for and developing new immunotherapy markers. For cervical cancer diagnosis, it has been shown that ctDNA mutations can reflect HPV integration sites. In terms of cervical cancer prognosis monitoring, cohort studies focused on the application of HPV ctDNA in the field of cervical cancer prognosis monitoring. The aim of this study is to design a customized ctDNA probe for cancer patients through a priori tumor detection method, and to guide recurrence monitoring plan and implement individualized adjuvant therapy according to the results, and to explore personalized biomarkers to guide cervical cancer immunotherapy. To explore the possibility of customized ctDNA detection as a diagnostic marker for cervical cancer. To explore the predictive and prognostic value of customized ctDNA dynamic monitoring. A multi-arm cohort clinical study is planned. To comprehensively study the treatment strategy of advanced and recurrent cervical cancer and explore the related biomarkers through the customized dynamic monitoring of ctDNA in patients with advanced and recurrent cervical cancer. A total of 60 patients with cervical cancer were enrolled.
Interventions
None listed
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. be willing and able to provide written informed consent/consent for the trial. 2. Be 18 years of age or older on the date of signing the informed consent form. 3. patients with histologically or cytologically documented locally advanced, advanced, or first recurrent cervical cancer. For treatment-naive patients, 4) no previous cancer treatment including chemotherapy or radiotherapy; Patients with an initial recurrence had not received any other cancer treatment, including chemotherapy or radiotherapy, after the diagnosis of an initial recurrence before enrollment. 5\) measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. 6\) willing and able to provide tumor lesions or excisional biopsy tissue. 7) a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. Demonstrate adequate organ function. 8\) a negative pregnancy test in a fertile female patient.
Exclusion criteria
1. be diagnosed as immunocompromised or receiving systemic steroid therapy or any other form of immunosuppressive therapy. 2. a known history of active tuberculosis (Mycobacterium tuberculosis). 3. have a known other malignancy that is progressing or requires active treatment. 4. known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 5. have an active autoimmune disease requiring systemic treatment within the past 2 years. 6. known history or any evidence of active noninfectious pneumonia. 7. active infection requiring systemic therapy. 8. there is historical or current evidence of any condition, treatment, or laboratory abnormality that could confound the trial results, interfere with the patient's participation throughout the trial, or that the treatment investigator believes participation would not be in the patient's best interest. 9. psychiatric or substance abuse disorders known to interfere with compliance with trial requirements. 10. be pregnant or breastfeeding, or expect to become pregnant or give birth to a child within the intended duration of the trial. 11. had a known history of human immunovirus (HIV) (HIV 1/2 antibodies). 12. known to have active hepatitis B (e.g., HBsAg reactive) or hepatitis C. 13. received live vaccine within 30 days of planned initiation of study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Somatic mutation detection by WES | from Des 2024 to Oct 2026 |
Contacts
Primary ContactLi
Outcome results
None listed